Efficacy and safety of combination behavioral activation for smoking cessation and varenicline for treating tobacco dependence among individuals with current or past major depressive disorder: A 2 × 2 factorial, randomized, placebo-controlled trial

Monday, July 31st, 2023

This randomized, placebo-controlled study examined the efficacy and safety of behavioral activation for smoking cessation versus standard behavioral treatment (with each treatment administered in combination with placebo or varenicline) in 300 adult smokers with current or past major depressive disorder. As part of the study, smoking abstinence was confirmed via measurement of expired CO using the Vitalograph BreathCO monitor.